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Abstract
Antibodies directed to cyclic citrullinated peptides (anti-CCP) are highly speciﬁc for rheumatoid arthritis (RA) and can easily
be detected in sera by using commercially available immunoassays. The second version of the anti-CCP test (anti-CCP2)
demonstrated high speciﬁcity (89–98%) and good sensitivity (41–88%) for RA. Commercially available ELISA methods
from three different companies are on the market. All three CCP2 assays show similar results as all CCP2 assays use the same
antigen-coated plates. This study was an evaluation of a new automated method for the determination of anti-CCP2 in a
routine laboratory setting. Five hundred and fourty three serum samples were tested for anti-CCP2 within normal routine
diagnostic using a commercially available ELISA and retested with a prelaunch version of a new and fully-automated method
(EliAe). The results were comparable. The new automated assay is easy to use and demonstrated a diagnostic sensitivity of
80% and speciﬁcity of 97%.
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Introduction
Rheumatoid arthritis (RA) is the most common
inﬂammatory joint disease with a prevalence between
0.5 and 1% worldwide (Lawrence et al. 1998). The
diagnosisismainlybasedonclinicalsignsandsymptoms
according to latest recommendations in 1987 (Arnett
et al. 1988). Within these seven diagnostic criterias,
detectionofIgMrheumatoidfactor(RF)inserumisthe
only recommended laboratory marker. Though IgM-
RF is measured in most studies and is the most often
ordered autoantibody test in laboratory diagnosis, its
speciﬁcity for diagnosing RA is limited. At very low
levels IgM-RF is present in sera of most people. High
concentrations of IgM-RF are not only detected in RA
but also in other conditions with polyclonal
stimuli to B-cells like viral and bacterial infections or
chronic inﬂammations other than RA. The need for a
better laboratory marker with a higher disease-related
speciﬁcity and sensitivity was always evident.
A very speciﬁc antibody for RA was ﬁrst described
by Nienhuis and Mandema (1964) which is called
antiperinuclear factor (APF) as these antibodies
bound to constituents of the keratohyaline granules
which are located close to the nucleus of buccal
mucosa cells of adult people. The APF showed an
acceptable sensitivity and compared to RF a much
higher speciﬁcity (Hoet et al. 1991). Nevertheless, the
test was never used for routine testing in case of
practical inconvenience. The test required carefully
selected buccal mucosa cells which were differentiated
enough to contain the perinuclear factor. Experienced
laboratory technicians were needed to perform the test
based on indirect immunoﬂuorescence and to
recognize the different immunoﬂuorescent patterns.
In 1979, another group of RA speciﬁc antibodies,
the so-called antikeratin antibodies (AKA) was
described (Young et al. 1979). The AKA bind to
keratin-like structures in the corniﬁed layer of stratum
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detected by indirect immunoﬂuorescence on rat
oesophagus cryostat sections and some laboratories
started to offer AKA measurement within normal
routine diagnostics. The speciﬁcity for RA was
comparable to APF (Hoet and van Venrooij 1992)
and it could be demonstrated that AKA also precede
the onset of RA (Kurki et al. 1992).
It was shown that APF and AKA target the same
antigen (Sebbag et al. 1995) identiﬁed as the epithelial
protein ﬁlaggrin (ﬁlament aggregating protein) which
is involved in the organization of cytoskeletal
structures. Several ﬁlaggrin subunits result from
proteolytical cleavage of proﬁlaggrin during differen-
tiation of epithelial cells. Proﬁlaggrin is ﬁrst
dephosphorylated and about 20% of the basic arginine
residues are converted into neutral citrulline residues
by the enzyme peptidylarginine deiminase. It has been
documented that the modiﬁcation to a citrulline
containing protein is essential for the autoantigenicity
of ﬁlaggrin (Schellekens et al. 1998) and citrullinated
ﬁllaggrin is the antigen targeted by APF and AKA.
Immunoblotting assays and enzyme-linked immuno-
sorbent assays (ELISA) using ﬁlaggrin puriﬁed from
human skin as antigen detected antiﬁlaggrin anti-
bodies (AFA) in 42% of patients with RA with a
speciﬁcity of 99% (Vincent et al. 1998). Using in vitro
deiminated recombinant ﬁlaggrin increased the
number of positive RA sera to 52% (Aho et al.
1999). Sensitivity and speciﬁcity of AFA seemed to be
dependent on the method of ﬁlaggrin puriﬁcation and
on the difﬁculty to obtain antigen preparations with
reproducable citrullin content. This technical pro-
blem could be solved by using isolated citrullinated
ﬁlaggrin peptides as antigen but it became apparent
that sera from different RA patients show different
patterns of reactivity indicating the heterogenity of the
autoimmune response. Using a combination of nine
citrullinated peptide variants a sensitivityof 76% and a
speciﬁcity of 96% were detected. The test was
improved and simpliﬁed using a cyclic variant of a
citrullinated peptide called anti-cyclic citrullinated
peptide (CCP) test. This ﬁrst anti-CCP test revealed
a high diagnostic speciﬁcity of about 98% and a
sensitivity around 70% (Boekel et al. 2002).
To improve, the anti-CCP test peptides from
dedicated libraries of citrullinated peptides were
tested with RA sera to select the most reactive species.
The selected peptides were made cyclic to ensure the
exposure of the antigenic citrulline structure. This
investigation resulted in the second generation anti-
CCP assay which is sold worldwide as CCP2 assay
(Vossenaar and Venrooij 2004).
Till the end of 2003, there were three distributors
(Euro-Diagnostica, Arnhem, The Netherlands; Axis-
Shield Diagnostics Ltd., Dundee, UK; Inova Diagno-
stics Inc., San Diego, CA) selling the CCP2test. CCP2
is a brand name and all commercial available
immunoassays use the same antigen and the same
antigen-coated plates but differ in working procedures.
The results of all three assays are similar (Dubucquoi
etal.2004, Garcia-Berrocaletal.2005).The anti-CCP
test has a comparable sensitivity but a much higher
speciﬁcity than the IgM-RF test in diagnosing RA
(Table I) and it is not surprising that anti-CCP testing
has increasing acceptance in laboratory medicine. In
November 2004, Sweden Diagnostics afﬁliate of
Pharmacia Diagnostics AB Freiburg, Germany,
launched the ﬁrst fully-automated testing system for
CCP antibodies called ELIAe CCP. This assay was
tested in a prelaunch version on samples collected
consecutively from patients coming to the Rheumato-
logy Unit of our hospital.
Materials and methods
Five hundred and forty three serum samples
(395female,148male)from outpatientsofourhospital
were tested for anti-CCP routinely by a commercially
available ELISA (Inova Diagnostics Inc.) and retested
Table I. Sensitivity and speciﬁcity of anti-CCP and IgM-RF antibody measurements in sera of patients with RA.
Anti-CCP IgM-Rf
Source Sensitivity (%) Speciﬁcity (%) Sensitivity (%) Speciﬁcity (%)
Schellekens et al. (2000) 68 98 54 91
Goldbach-M. et al. (2000) 50 90 66 87
Bizzaro et al. (2001) 41 98 62 84
Bas et al. (2002) 68 96 75 74
Jansen et al. (2002) 43 98 50 93
Lee and Schur (2003) 66 90 72 80
Suzuki et al. (2003) 88 89 70 82
Zeng et al. (2003) 47 97 59
Saraux et al. (2003) 47 93 41
Araki et al. (2004) 81 92
Dubucquoi et al. (2004) 65 96 60 70
Girelli et al. (2004) 71 95 91 31
Vallbracht et al. (2004) 64 97 66 82
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of Pharmacia Diagnostics AB Freiburg), an automated
testsystemfor thedeterminationofanti-CCP.Thetests
of both companies correspond to the so-called anti-
CCP2 test. Results were classiﬁed according to the
recommendations of the manufacturers. The ELISA
from Inova categorizes negative (,20U/ml), weak
positive (20–39U/ml), moderate positive (40–
59U/ml) and strong positive (.60U/ml). EliAe from
Pharmacia gave a preliminary recommendation with
negative (,7U/ml), borderline positive (7–10U/ml)
and positive (.10U/ml).
Serum samples were drawn from patients consecu-
tively coming to our hospital with joint problems.
CCP was routinely tested in all patients with clinical
suspect for RA or other inﬂammatory joint diseases
and from patients with prediagnosed RA but not yet
tested on anti-CCP. After detection of anti-CCP with
both methods, patients’ ﬁles were screened to evaluate
the diagnosis. RA was diagnosed according to the
revised ACR criteria (Arnett et al. 1998).
Results
Overall, there was a good agreement in the results of
both assays (Table II). Among the positive samples
detected by ELISA, 12 samples were negative by
EliAe. These samples were from patients who were
diagnosed in 1 case as possible RA, in 4 cases as non-
RA and in 7 cases a diagnose was not known.
Thirteen out of 88 positive samples tested by EliAe
were negative in the Inova assay. Twelve of these
samples were only weak positive with concentrations
below 29U/ml and only one sample from a patient
diagnosed as non-RA was strong positive. The 12
weak positive samples were in 8 cases from patients
with RA (Table III). Three samples were moderate to
strong positive in ELISA but negative in EliAe. None
of these three samples was from a patient with deﬁnite
or possible RA.
Inseraof66patientswith deﬁnite RA(TableIV),the
ELISA and EliAe revealed 45 (68%) and 53 (80%)
positive results, respectively. In the group of patients
withpossibleRA,anti-CCPresultswereidentical.Inthe
non-RA group results were almost identical with 11
positive and 317 negative samples in ELISA versus 10
positive and 318 negative samples in EliAe.T h e
diagnostic sensitivity and speciﬁcity were 68.2 and
96.9% in the ELISA and 80.3 and 97.0% in the EliAe,
respectively.
Sera were collected from 16 patients at two different
times and analysed blinded. All results were highly
reproducible in both assay systems though all samples
were analyzed in different assay runs.
Discussion
Antibodies directed to citrullinated proteins and their
association to RA are well known since several years.
These antibodies occur in patients with RA and can
even be detected in sera years before onset of disease
symptoms (Kurki et al. 1992, Rantapaa-Dahlqvist
et al. 2003, Nielen et al. 2004). The development of
synthetic citrullinated proteins provided the use as
antigens in immunoassays. Since test improvement by
making cyclic variants of citrullinated peptides as
antigens in commercially available ELISAs, there is an
increasing interest in testing these antibodies as
diagnostic and prognostic markers in patients with
RA (Kroot et al. 2000, Schellekens et al. 2000,
Vasishta 2002, Bas et al. 2003, Meyer et al. 2003,
Vencovsky et al. 2003, Berglin et al. 2004, Forslind
et al. 2004, van Gaalen et al. 2004a,b, Kastbom et al.
2004, Lopez-Hoyos 2004, Maddali Bongi et al. 2004,
van Venrooij et al. 2004, Lindqvist et al. 2005, Nielen
et al. 2005, Raza et al. 2005).
In 2004, there were three commercial second-
generation ELISAs for the measurement of anti-CCP
antibodies marketed as anti-CCP2 tests. All CCP-2 Table II. Number of serum samples with negative, borderline or
weak positive and positive results comparing ELISA and EliAe.
Automated (EliAe Pharmacia)
ELISA Inova Negative Borderline Positive
Negative 442 1 13
Weak positive 9 0 7
Moderate positive 2 0 5
Strong positive 1 0 63
The ELISA from Inova categorizes negative ,20U/ml, weak
positive 20–39U, moderate positive 40–59U and strong positive
(.60U). The automated EliAe from Sweden Diagnostics
categorizes negative ,7U, borderline 7–10U and positive .10U.
Table III. Incidence of deﬁnite RA in those patients whose sera
revealed different results in both anti-CCP2 assays.
Rheumatoid arthritis
ELISA EliAe n Yes Possible No Unknown
Negative Positive 13 8 1 2 2
Positive Negative 3 – – 1 2
Table IV. Incidence of positive or negative results of anti-CCP
antibodies in serum samples of different patient groups.
ELISA anti-CCP EliAe anti-CCP
Diagnosis n Positive Negative Positive Negative
RA 66 45 21 53 13
Possible RA 42 12 30 12 30
Non RA 328 11 317 10 318
Unknown 107 19 88 14 93
Total 543 87 456 89 454
Anti-CCP in routine 133tests use the same second-generation synthetic
citrullinated peptide antigen bound to the same
surface of a microwell plate. The tests differ in
handling procedures and other components of the
assay system but reveal similar results. Comparing to
one of these three ELISA’s, we tested a new and fully
automated CCP-2 assay in a prelaunch version. The
results were comparable and both assays showed the
same speciﬁcity. We found some difference between
the two assays in sensitivity. This difference is mainly
based on 8 samples of RA patients, which were
negative in the ELISA and weak positive in the EliAe.
Comparing to data from literature, the sensitivity of
80% for the automated assay ﬁts to results from anti-
CCP2 ELISAs with optimum cut-off values (Garcia-
Berrocal et al. 2005).
IgM rheumatoid factor has been commonly used as
serological marker of RA. In all publications, anti-
CCP demonstrated a higher speciﬁcity and a
comparable or slightly higher sensitivity than IgM-
RF. There is no doubt that anti-CCP is a valuable
serum marker for the diagnosis of RA. Different
analytical procedures may be one of the reasons that
measurement of IgM-RF is still offered in most
laboratories but not anti-CCP. IgM-RF is usually
measured automatically on common analyzers, which
are used in routine laboratory diagnostics. EliAe anti-
CCP is the ﬁrst fully automated method for the
determination of anti-CCP with all advantages of an
automated analytical method like standardized con-
ditions and short hands-on-time.
ThenewautomatedimmunoassayEliAeformeasur-
ing anti-CCP is easy to use and shows reliable results
with sensitivity and speciﬁcity for diagnosing RA
comparabletogivenanti-CCP2ELISAsonthemarket.
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